A carregar...
Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy
DNA is the well-known molecular target of current platinum-based anticancer drugs; consequently, their clinical use is severely restricted by their systemic toxicities and drug resistance originating from non-selective DNA damage. Various strategies have been developed to circumvent the shortcomings...
Na minha lista:
| Publicado no: | Biochem Pharmacol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5287571/ https://ncbi.nlm.nih.gov/pubmed/27381943 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2016.06.019 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|